REFERENCES
- Kozak I, Morrison V, Clark T, Bartsch D, RoLee B, Falkenstein I, Tammewar A, Mojana F, Freeman W. Discrepancy between fluorescein angiography and optical coherence tomography in detection of macular disease. Retina 2008;28:538–544.
- Joshi M, Garretson B. Paclitaxel maculopathy. Arch Ophthalmol 2007;125:709–710.
- Smith S, Benz M, Brown D. Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol 2008;126:1605–1606.
- Teitelbaum B, Tresley D. Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 2003;40:277–279.
- Telander D, Sarraf D. Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Sem Ophthalmol 2007;22:151–153.
- Berson E, Lessell S. Paraneoplastic night blindness with malignant melanoma. Am J Opthalmol 1988;106:307–311.
- Weinstein JM, Kelman SE, Bresnick GH, Kornguth SE. Paraneoplastic retinopathy associated with antiretinal bipolar cell antibodies in cutaneous malignant melanoma. Ophthalmology 1994;101:1236–1243.
- Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Eng J Med 1995;332:1004–1014.
- O’Day S, Gonzalez R. Lawson D. Weber R. Hutchins L. Anderson C. Haddad J. Kong S. Williams A. Jacobson E. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol 2009;27:5452–5458.
- Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998;16:3426–3432.
- Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997;15:3149–3155.
- Esmaeli B, Valero V, Ahmadi MA, Booser D. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology 2001;108:994–995.
- Seidman AD, Barrett S, Canezo S. Photopsia during 3-hour paclitaxel administration at doses > or = 250 mg/mq. J Clin Oncol 1994;12:1741–1742.
- Capri G, Munzone E, Tarenzi E, Fulfaro F, Gianni L, Caraceni A, Martini C, Scailoli V. Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst 1994;86:1099–1101.
- Scaioli V, Caraceni A, Martini C, Palazzini E, Tarenzi E, Fulfaro F, Munzone E. Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy. J Neuro-Oncol 1995;25:221–225.
- Jampol LM. Niacin maculopathy. Ophthalmology 1988;95:1704–1705.